Phage lysin that specifically eliminates Clostridium botulinum Group I cells by Zhang, Zhen et al.
1
Vol.:(0123456789)
Scientific Reports |        (2020) 10:21571  | https://doi.org/10.1038/s41598-020-78622-6
www.nature.com/scientificreports
Phage lysin that specifically 
eliminates Clostridium botulinum 
Group I cells
Zhen Zhang, Meeri Lahti, François P. Douillard, Hannu Korkeala & Miia Lindström*
Clostridium botulinum poses a serious threat to food safety and public health by producing potent 
neurotoxin during its vegetative growth and causing life-threatening neuroparalysis, botulism. 
While high temperature can be utilized to eliminate C. botulinum spores and the neurotoxin, non-
thermal elimination of newly germinated C. botulinum cells before onset of toxin production could 
provide an alternative or additional factor controlling the risk of botulism in some applications. Here 
we introduce a putative phage lysin that specifically lyses vegetative C. botulinum Group I cells. This 
lysin, called CBO1751, efficiently kills cells of C. botulinum Group I strains at the concentration of 
5 µM, but shows little or no lytic activity against C. botulinum Group II or III or other Firmicutes strains. 
CBO1751 is active at pH from 6.5 to 10.5. The lytic activity of CBO1751 is tolerant to NaCl (200 mM), 
but highly susceptible to divalent cations  Ca2+ and  Mg2+ (50 mM). CBO1751 readily and effectively 
eliminates C. botulinum during spore germination, an early stage preceding vegetative growth and 
neurotoxin production. This is the first report of an antimicrobial lysin against C. botulinum, presenting 
high potential for developing a novel antibotulinal agent for non-thermal applications in food and 
agricultural industries.
Clostridium botulinum is a Gram-positive, spore-forming anaerobic bacterium that produces botulinum neuro-
toxin (BoNT). BoNT causes botulism, a potentially fatal flaccid paralysis, in humans and  animals1. The patho-
genic process is initiated by spore germination and outgrowth of C. botulinum into vegetative, toxinogenic 
cultures in food or feed, or in the host gastrointestinal tract or in deep  wounds2. Thus, botulism can manifest 
as an intoxication due to preformed BoNT or as a toxicoinfection from spores. C. botulinum is a heterogeneous 
taxon that comprises several genetically and physiologically distinct species with the common feature of botu-
linum neurotoxin production. Human botulism is predominantly associated with C. botulinum Group I and II. 
Sporadic cases of human botulism are also related to BoNT-producing Clostridium baratii (also called Group 
V) and BoNT-producing Clostridium butyricum (also called Group VI). Animal botulism is mainly associated 
with C. botulinum Group III. The link between botulism and Clostridium argentinense (also called Group IV) 
is  unclear2. Botulism is a rare but extremely serious condition, with a single case activating a national alert and 
outbreak investigation, and causing enormous economic  loss3. High-temperature processing in the food industry 
is the most effective method for inactivation of C. botulinum spores and the neurotoxin, but often compromises 
nutritional and sensory qualities of food  products4. There is a growing interest in development of novel methods 
alternative to thermal process to control the botulism  hazard5,6.
Bacteriophage lysins are natural hydrolytic enzymes that lyse host bacterial cells by disrupting the pepti-
doglycan  layer7. In Gram-positive bacteria, many phage lysins consist of an amino-terminal catalytic domain, 
which cleaves one of the major bonds in the peptidoglycan, and a carboxyl-terminal binding domain, which 
recognizes unique carbohydrate epitopes of cell wall polysaccharides. The synergistic action of both domains 
confers potent antimicrobial activity selectively against specific host bacteria, which is a distinctive advantage over 
classical antibiotics and chemical preservatives. Moreover, the biodegradable nature of proteinaceous phage lysins 
is a considerable benefit for potential applications in food and feed safety and in  therapeutics8–10. A number of 
phage lysins from a variety of host bacteria have been  characterized11,12. Commercial applications of phage lysins 
have also progressed rapidly in developing treatments for microbial infections and solutions to improve food 
 safety13–15. Clostridium perfringens is one of the most extensively studied anaerobic Gram-positive bacteria with 
characterized phage lysins and identified application potential. To date, ten lysins have been  characterized16–24. 
A series of further studies have significantly improved the application potential of these lysins in prevention of 
C. perfringens-associated food-borne illness and enteric diseases of domestic animals, or as a diagnostic tool in 
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the detection of C. perfringens25,26. Two phage lysins from Clostridium difficile and one from each of Clostridium 
tyrobutyricum and Clostridium sporogenes have been identified, all showing specific antimicrobial effects against 
the host bacterial  species27–30. There is no report on phage lysins against C. botulinum. None of the currently 
known lysins was reported to possess lytic activity against C. botulinum. A phage lysin acting specifically against 
C. botulinum would allow a novel non-thermal solution to control botulism hazards in foods or feeds.
Here we report a putative phage lysin, CBO1751, identified in C. botulinum Group I strain ATCC3502. We 
demonstrate that recombinantly expressed CBO1751 has specific lytic activity against cells of C. botulinum 
Group I. We show that CBO1751 can effectively eliminate newly germinated cells, offering potential for early 
interruption of the pathogenic process of C. botulinum.
Results
Analysis of the putative phage lysin gene. CBO1751 was identified by prophage region analysis of 
the genome of C. botulinum Group I strain ATCC3502 using the PHASTER web  server31. cbo1751, encoding a 
putative phage lysin, was found in one of two intact prophage regions. The amino acid sequence of CBO1751 is 
predicted to encode an enzymatically active domain (EAD) of N-acetylmuramoyl-L-alanine amidase (cd02696) 
on the N-terminal side and a cell wall‐binding domain (CBD) of bacterial Src homology 3 (SH3b) on the C-ter-
minal side (Fig. 1a), suggesting that CBO1751 is an amidase lysin. CBO1751 shared an overall identity in amino 
acid sequence of 39% with the CS74L lysin of C. sporogenes and < 30% identity in amino acid sequence with other 
known lysins in Clostridium spp. (Supplementary Fig. S1). The amino acid sequences of EADs on the N-terminal 
side between the CBO1751 and CS74L lysins showed 58% identity (Fig. 1b), whereas the CBDs on the C-termi-
nal side presented only 11% identity, suggesting that only the EADs of CBO1751 and CS74L are phylogenetically 
related. We further compared the amidase EADs of CBO1751 and CS74L with PlyPSA, a Listeria endolysin with 
four characterized catalytic residues responsible for zinc-dependent amidase  activity32. Although the EADs of 
CBO1751 and CS74L shared < 30% amino acid identity to the EAD of PlyPSA, the alignment showed that all 
the corresponding catalytic residues are conserved in CS74L and CBO1751 (His9, Glu24, His80 and Glu141; 
Fig. 1b), implying that CBO1751 might have amidase activity similar to CS74L and PlyPSA. The SH3b CBD of 
CBO1751 showed high sequence divergence to the SH3b of other known lysins, including the well-studied SH3b 
domain (< 10% pairwise sequence identity) of staphylolytic  lysins33–35.
We then investigated the prevalence of CBO1751 homologs in C. botulinum and in other bacteria. BLAST 
search found 45 CBO1751 homologs with > 80% amino acid identity in genomes of 152 C. botulinum Group I 
strains (Supplementary Table S1). BLAST search also identified 16 CBO1751 homologs with > 80% amino acid 
identity in genomes of 45 C. sporogenes strains. In addition, three CBO1751 homologs with > 80% amino acid 
identity were found in both C. botulinum Group I and C. sporogenes strains. BLAST analysis did not find any 
full-length CBO1751 homologs in C. botulinum Group II-IV or in other bacteria. The analysis indicates that 
CBO1751, a putative novel lysin, is highly conserved in a number of C. botulinum Group I and C. sporogenes 
strains.
Characterization of lytic activity and host specificity of CBO1751. Through cloning of cbo1751 
into pET21b vector and expression in Escherichia coli Rosetta 2(DE3) pLysS cells, we obtained the purified 
CBO1751 protein (yield approximately 15 mg/l of E. coli culture) with molecular weight of 29 kDa using affinity 
chromatography (Fig. 1a). To assess if CBO1751 exerts lytic activity on C. botulinum, turbidity reduction assay 
was performed using vegetative cell suspension of C. botulinum ATCC3502 with initial optical density at 600 nm 
 (OD600) adjusted to approximately 1. In the cell suspension supplemented with protein-free dialysis buffer (DB), 
 OD600 remained steady across all time points and was 0.94 for 60 min (Fig. 2a). However, a substantial reduction 
in  OD600 was observed in cell suspensions supplemented with 0.2 to 5 µM of CBO1751, suggesting lytic activ-
ity of CBO1751 against C. botulinum ATCC3502 vegetative cells. The lytic activity of CBO1751 showed time 
and dose-dependency. The minimum  OD600 (0.17) was reached at 60 min when treated with 5 µM of CBO1751 
(Fig. 2a). To avoid variation in vegetative culture and cell suspension preparations between different batches, we 
prepared one stock of frozen cells of C. botulinum ATCC3502 and used this as substrate to determine the lytic 
activity of CBO1751. Unlike fresh vegetative cells, frozen cells with the control DB treatment showed marked 
drop of  OD600, indicating autolysis during turbidity reduction assay (Fig. 2b). Nevertheless, CBO1751 still exhib-
ited time and dose-dependent activity over a range of concentration from 0.02 to 5 µM. The  OD600 values after 
subtraction of the control DB values were used to generate linear regression slopes (ΔOD600/min) of lysis curves. 
The enzymatic activity of CBO1751 was determined as 6,600 units/mg based on the linear equation of the slopes 
of the treatments of 0.02 to 0.3 µM CBO1751 (Fig. 2b).
We then tested the specificity of the lytic activity of CBO1751 against vegetative cell suspensions of a range of 
C. botulinum strains and other Firmicutes strains by comparing the CBO1751/DB-treated  OD600 ratio at 30 min 
and 60 min. Of the seven C. botulinum Group I strains tested, the CBO1751/DB-treated  OD600 ratio decreased 
markedly at both timepoints and varied from 0.18 to 0.41 at 60 min, whereas the values for four C. botulinum 
Group II strains were above 0.88 at 30 min and decreased only slightly to 0.68 to 0.72 at 60 min (P < 0.001, 
Fig. 2c). No marked reduction in  OD600 was observed in C. botulinum Group III strains. These results suggest 
that CBO1751 has significant lytic activity against C. botulinum Group I strains, mild lytic activity against C. 
botulinum Group II strains, and no lytic activity against C. botulinum Group III strains. CBO1751 also showed 
a mild lytic activity against C. sporogenes NINF45, C. baratii CCUG24033 and C. butyricum BL86/13 with the 
CBO1751/DB-treated  OD600 ratios at 60 min of 0.60, 0.69 and 0.64, respectively. No reduction in  OD600 was 
observed for C. perfringens ATCC13124, C. difficile CD-UN5/11–14, Bacillus cereus ATCC14579 or for Bacillus 
subtilis 1012M15, suggesting that CBO1751 has no lytic activity against these Firmicutes.
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We further performed viable cell enumeration of C. botulinum Group I strains ATCC3502, NCTC2916, 
and 62A cell suspensions treated with CBO1751 using the most-probable-number (MPN) method. Cell sus-
pensions were equally distributed in two aliquots and treated with 5 µM of CBO1751 or the control DB for 
60 min. To exclude the contribution of spontaneous cell death during the treatment, cell counts of the three 
strains after CBO1751 treatment were compared to those after DB treatment. While the cell counts of strains 
ATCC3502, NCTC2916, and 62A were estimated to be 5.5 × 107, 4.7 × 107 and 6.4 × 107 MPN/ml after the 60-min 
DB treatment, counts of 3.7 × 105, 1.6 × 104 and 5.5 × 103, respectively, were measured with the CBO1751 treat-
ment (Fig. 2d), indicating about 2 to 4 log units difference in reduction of viable cell counts between CBO1751 
treatment and the control DB treatment. The result provides further evidence for the lytic activity of CBO1751 
against C. botulinum Group I strains.
Effect of pH and salt on the lytic activity of CBO1751. We conducted turbidity reduction assay to 
evaluate the influence of pH and salt type and concentration on the lytic activity of CBO1751 using frozen 
cells of C. botulinum ATCC3502. To exclude the effect of autolysis during the assays, the lysis curves with 5 µM 
CBO1751 treatment were presented after subtraction of the corresponding  OD600 values of DB treatment under 
the same reaction conditions. CBO1751 at 5 µM caused a marked reduction of  OD600 at pH from 7.5 to 10.5. The 
Figure 1.  Features of CBO1751. (a) Schematic representation of the two domains of CBO1751 and SDS-PAGE 
analysis of purified CBO1751. Left lane of gel image, Precision Plus Protein Dual Color Standards (Bio-Rad, 
Hercules, USA). Right lane, eluted his-tagged CBO1751. The original gel is shown in Supplementary Fig. S2. (b) 
Amino acid sequence alignment of amidase EAD of CBO1751 with Clostridium sporogenes CS74L and Listeria 
monocytogenes PlyPSA. The conserved catalytic residues are marked in yellow.
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slopes of the lysis curves were similar at pH from 8.5 to 10.5 and were slightly deeper than that at pH 7.5, sug-
gesting that an alkaline pH is more favorable for the lytic activity of CBO1751 than a neutral pH. The CBO1751 
treatment caused only moderate reduction in  OD600 at pH 6.5 and no reduction at pH 4.5, 5.5, and 11.5 (Fig. 3a). 
The results suggest that CBO1751 is active over a pH range of 6.5 to 10.5, with optimal activity at alkaline pH. 
We also evaluated the effect of salt ions on the enzymatic activity of CBO1751. Due to the addition of 5 µl of 
CBO1751 (dialyzed against DB buffer comprising 500 mM NaCl) to the final reaction mixture (200 µl), the low-
est NaCl concentration tested was 12.5 mM. The CBO1751 treatment only caused a minor  OD600 reduction in 
the presence of 400 mM NaCl (Fig. 3b). By contrast, similar lysis curves were observed with 12.5 and 100 mM 
NaCl. Due to cell autolysis triggered by the high concentration of NaCl, lysis curve at 200 mM NaCl flattened 
after 5 µM CBO1751 treatment for 5 min, but kept a deep slope during the first 4 min of CBO1751 treatment, 
which is comparable to that observed with 12.5 or 100 mM NaCl. These results suggest that NaCl up to 200 mM 
(1.2%) does not strongly affect the lytic activity of CBO1751. The lytic activity of CBO1751 was sensitive to the 
presence of divalent salts  CaCl2 and  MgSO4. CBO1751 treatment showed only a minor reduction of  OD600 in 
the presence of 50 mM  CaCl2 and  MgSO4, and even less reduction with 100 and 200 mM  CaCl2 and  MgSO4 
(Fig. 3c,d). The results suggest that a small amount of divalent cations significantly attenuates the lytic activity 
of CBO1751.
Elimination of newly germinated cells by CBO1751. Since lysins kill bacterial cells by degrading 
the peptidoglycan cell wall, it is conceivable that CBO1751 may lyse newly germinated C. botulinum Group I 
cells once the peptidoglycan cell wall has been exposed. To confirm this, we prepared a germinating culture in a 
microfluidic system under anaerobic conditions and observed the effect of CBO1751 using time-lapse micros-
copy. After incubation of C. botulinum ATCC3502 spores in tryptone-peptone-glucose-yeast extract (TPGY) 
medium in a microfluidic chamber for 6 h, most of the phase-bright spores germinated and outgrew into thread-
shaped vegetative cells that retained the empty shell of the spore coat at one end of the filament. Then, CBO1751 
suspended in PBS (concentration optimized to 20 µM) was perfused into the chamber to replace TPGY. After 
CBO1751 perfusion for about 12 min, an intensive cell lysis was detected in newly germinated cells (Fig. 4 and 
Supplementary Video S1). Practically all cells were eliminated within 25 min. In contrast, germinated cells main-
tained their intact cell shape after perfusion of control DB suspended in PBS for 50 min, and no cell lysis was 
observed (Supplementary Fig. S3). These observations confirmed the lytic activity of CBO1751 against newly 
germinated C. botulinum Group I cells.
Figure 2.  Lytic activity of CBO1751. (a) Lytic activity of CBO1751 as analyzed by measuring  OD600 of 
Clostridium botulinum ATCC3502 vegetative cell suspension over 60 min after addition of DB or 0.2 to 
5 µM of CBO1751. (b) Determination of lytic activity of CBO1751. Left: Lytic activity analysis by measuring 
 OD600 of C. botulinum ATCC3502 frozen cell suspension over 30 min after addition of DB or 0.02 to 5 µM of 
CBO1751. Right: Linear regression plot of the slopes (ΔOD600/min) of lysis curves against the four CBO1751 
concentrations (0.02, 0.05, 0.1 and 0.3 µM). All  OD600 values of (a) and (b) were normalized to an initial 
 OD600 of 1. (c) Lytic activity of CBO1751 against different Firmicutes strains as analyzed by comparing the 
ratio between  OD600 values of 5 µM CBO1751-treated against DB-treated vegetative cell suspensions for 30 
and 60 min. (d) Most probable number (MPN) enumeration of C. botulinum ATCC3502, NCTC2916 and 
62A cells after treatment with 5 µM of CBO1751 or DB for 60 min. All results are presented as means of three 
replicates ± standard deviations. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Discussion
Bacteriophage lysins are the essential peptidoglycan-degrading proteins that are required by double-stranded 
DNA (dsDNA) phages for the lysis of host bacterial cell wall and release of their viral progenies to extracellular 
space. With dsDNA phages, lysins are exported by a holin-dependent or -independent mechanism through the 
bacterial cytoplasmic membrane into the periplasmic space and therefrom access the peptidoglycan substrate 
in the cell  wall36. Therefore, phage lysins are primarily defined as endolysins. However, these enzymes can also 
degrade the peptidoglycan layer of Gram-positive bacterial cells exogenously and cause immediate cell  lysis37. 
This feature underpins the broad application of phage lysins as natural antimicrobials with technical feasibility. 
In recent decades, the ever-increasing number of characterized phage lysins exhibits large antimicrobial potential 
against a list of pathogenic and food spoilage  bacteria11,12.
Novel approaches alternative to thermal treatment would be a welcome addition in the toolbox for controlling 
the serious food and feed safety risks caused by the neurotoxigenic C. botulinum. Moreover, the use of natural 
antimicrobials in food products would reduce the need for chemical preservatives without compromising food 
safety. Here we demonstrate for the first time an active phage lysin efficiently killing C. botulinum. The lytic 
activity of CBO1751, originally identified in C. botulinum Group I strain ATCC3502, was verified with 5 µM 
CBO1751 leading to more than 2 log units reduction in C. botulinum cells in an hour. We also demonstrated 
efficient elimination of C. botulinum cells newly germinated from spores by addition of CBO1751, suggesting a 
great potential for CBO1751 as an effective control strategy to interrupt the pathogenic process of C. botulinum 
at an early stage.
Figure 3.  Effects of pH, NaCl,  CaCl2 and  MgSO4 on the lytic activity of CBO1751. Lytic activity analysis by 
measuring  OD600 of Clostridium botulinum ATCC3502 frozen cells after addition of DB or 5 µM CBO1751 at 
pH from 4.5 to 11.5 (a) or in the presence of 12.5–400 mM NaCl (b), 0–200 mM  CaCl2 (c) or 0–200 mM  MgSO4 
(d). All  OD600 values were normalized to an initial  OD600 of 1 and adjusted by subtraction of the corresponding 
DB control values. Results are indicated as means of three replicates ± standard deviations.
Figure 4.  CBO1751 eliminates newly germinated cells of Clostridium botulinum ATCC3502 as analyzed by 
microscopy. First image from left, C. botulinum ATCC3502 spores in microfluidic chamber. Other images, 
representative time-lapse (min:sec) shots of cell lysing with 20 µM of CBO1751. Scale bars, 2 μm. Square-shaped 
dots are intrinsic pillars of the microfluidic chamber.
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pH is a major hurdle used in food  preservation38. In general, pH < 4.6 is required to control C. botulinum spore 
germination and  growth39. Food products and feeds with pH above 5 are favorable for C. botulinum  growth40. 
Since some low-acid or non-acid foods can contain a relatively high prevalence of C. botulinum  spores41–43, addi-
tional hurdles are needed to control the botulism hazard. Similar to phage lysins in other Clostridium spp.27–30, 
the lytic activity of CBO1751 exhibited a preference for neutral and alkaline pH, which allows CBO1751 to serve 
as an effective hurdle in these low-acid or non-acid foods to prevent production of neurotoxigenic cultures. 
Moreover, we observed robust cells lysis by CBO1751 in the presence of up to 200 mM (1.2%) NaCl, suggesting 
that the lytic activity of CBO1751 tolerates the NaCl levels added in many food products. While divalent metal 
cations were shown to be essential for the lytic activity of some zinc-dependent amidase  lysins44, they exerted 
inhibitory effects on the lytic activity of some other amidase  lysins24,28. Although CBO1751 has conserved zinc-
binding active sites in the amidase EAD, we observed marked reduction of its lytic activity in the presence of 
50 mM  CaCl2 and  MgSO4 (~ 0.6%). It is likely that an excess of divalent metal cations, once saturated the catalytic 
center of the amidase, affect the interaction between the lysin and the bacterial cell wall. The findings indicate 
that permitted levels of some divalent cation-based food additives might attenuate the effect of CBO1751 in 
elimination of C. botulinum. The proteinaceous nature of CBO1751 allows its safe application at high concentra-
tions. Further studies are warranted to optimize the antibotulinal potency and synergistic effects of CBO1751 
with other preservative hurdles in food products.
The host spectrum of CBO1751 is restricted to C. botulinum Group I, and to a lesser extent to C. botulinum 
Group II, C. sporogenes, C. baratii and C. butyricum. A rather rigid host specificity of CBO1751 was evidenced 
by a relatively high lytic activity of CBO1751 against all seven tested C. botulinum Group I strains, and a sub-
stantially lower activity against C. botulinum Group II, C. sporogenes, C. baratii and C. butyricum strains, and 
no activity against other Firmicutes. This is consistent with the identification of highly conserved CBO1751 
homologs (> 80% amino acid identity) in many C. botulinum Group I genomes but not in any strain of Group 
II, C. baratii and C. butyricum, and other Firmicutes. C. sporogenes is considered a nontoxigenic variant of C. 
botulinum Group I and forms a distantly related clade in the Group I phylogeny. Recent studies suggest that 
the C. sporogenes clade also contains some botulinum neurotoxigenic strains including CDC68016NT, AM370, 
AM1195, AM553, ATCC51387, Osaka05, Prevot594 and  Prevot166245,46. CDC68016NT, AM370 and AM1195 
carry putative phage lysins with > 80% amino acid identity to CBO1751 (Fig. 5 and Supplementary Table S1), 
implying that the three toxigenic C. sporogenes-like strains might be highly susceptible to CBO1751. However, 
strains AM553, ATCC51387, Osaka05, Prevot594 and Prevot1662 were found to possess putative lysins with 
only ~ 50% amino acid identity to CBO1751 (Fig. 5). Similarly, ATCC19397 and NCTC2916, two strains in the 
C. botulinum clade of Group I phylogeny, do not carry any highly conserved CBO1751 homolog, but possess 
CBO1751 homologs with 50% overall sequence identity and showed efficient lysis upon CBO1751 treatment. 
Intriguingly, the CBD of these CBO1751 homologs shared > 80% amino acid identity to the CBD of CBO1751 
(Fig. 5). The CBD is generally responsible for host specificity of lysins by binding to unique carbohydrate epitopes 
of cell wall polysaccharides in select bacterial species. Therefore, CBO1751 seems to have a broad host spectrum 
encompassing both clades in the C. botulinum Group I phylogeny. Further tests with more Group I strains will 
offer a better understanding of the host specificity of CBO1751. Moreover, to combat the wide heterogeneity of 
all BoNT-producing species, it is important to characterize lysins that target specifically each phylogenetically 
distinct group. This will offer not only additional antibotulinal lysins, but also a set of active EADs and CBDs for 
Figure 5.  Amino acid sequence alignment of CBO1751 and putative lysins of Clostridium botulinum 
CDC68016NT (LAGL01000000, contig00983, nt 2654–3412), AM553 (WP_061329857), ATCC51387 
(LAGD01000000, contig00030, nt 5143–5913), Osaka05 (GAE03455), Prevot594 (AJD31758), Prevot1662 
(LAGM01000000, contig00035, nt 5087–5857), ATCC19397 (ABS32796) and NCTC2916 (EDT81697). 
Sequences encoding putative CBDs are indicated in a green box.
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further domain shuffling and engineering to enhance the lytic activity and broaden the host spectrum, ultimately 
providing an all-encompassing-tool to control the botulism hazard.
As an example of a lysin CBD, the SH3b domain is found in many bacteria and is proposed to recognize pepti-
doglycan stem peptides and cross-bridges of the bacterial cell  wall33–35. In the case of the bacteriolysin lysostaphin, 
the SH3b domain specifically binds to pentaglycine cross-bridges that are a unique feature of  staphylococci33. 
We found that the CBO1751 CBD was highly conserved (> 80% amino acid identity) in a large number of C. 
botulinum Group I strains, but not in C. botulinum Group II or III, or other BoNT-producing Clostridium species. 
Except for some putative amidases in Clostridiaceae, CBO1751 CBD shared < 50% amino acid identity to some 
hypothetical surface proteins or peptidases in the family Bacillaceae. We speculate that the CBD of CBO1751 
might recognize the assumingly conserved peptidoglycan structure in C. botulinum Group I strains, thereby 
conferring its highest lytic activity against C. botulinum Group I. Further characterization of the CBO1751 CBD 
substrate will reveal the cell wall features of C. botulinum Group I. Due to specific binding, lysin CBDs show 
great potential for use as diagnostic tools in bacterial  detection13. A variety of CBD-based methods were devel-
oped for rapid detection of L. monocytogenes47, Staphylococcus aureus48, B. cereus25,49, C. perfringens25, and C. 
tyrobutyricum50. The rigid host specificity of CBO1751 might favor the development of a CBO1751 CBD-based 
diagnostic tool for detection of C. botulinum Group I in food and clinical samples.
In summary, our data show that the putative lysin CBO1751 efficiently lyses C. botulinum Group I cells 
and may provide a useful tool in non-thermal control of C. botulinum. Further studies are required to develop 
CBO1751-based antibotulinal applications in food products and rapid detection methods for C. botulinum, both 
approaches providing valuable novel contributions to controlling the botulism hazard.
Materials and methods
Computational analysis of phage lysin. The genome of C. botulinum Group I strain ATCC3502 
(Genbank accession number AM412317) was analyzed for prophage regions using the PHASTER web server. 
Sequence homology analysis was performed using BLASTp and NCBI Conserved Domain Search tool, and 
sequence alignment was done with ClustalW.
Bacterial strains and culture conditions. The bacterial strains used in this study are listed in Supple-
mentary Table S2. All clostridia were cultured in anaerobic TPGY medium at 30 °C (C. botulinum Group II 
strains) or 37 °C in an anaerobic workstation with an atmosphere of 85%  N2, 10%  CO2, and 5%  H2 (MK III; 
Don Whitley Scientific Ltd., West Yorkshire, UK). B. subtilis 1012M15, B. cereus ATCC14579 and E. coli Rosetta 
2(DE3) pLysS cells (Merck Millipore, Darmstadt, Germany) were grown in Luria–Bertani (LB) medium at 37 °C. 
When appropriate, growth media were supplemented with 100 μg/ml ampicillin and 34 μg/ml chloramphenicol.
Expression and purification of recombinant CBO1751. CBO1751 (GenBank accession number 
CAL83288) was commercially synthesized and cloned in the NheI/SalI restriction sites of pET21b to gener-
ate a C-terminal fusion construct with 6 × His tag (GenScript Biotech, Leiden, Netherlands). The vectors were 
transformed into E. coli Rosetta 2(DE3) pLysS cells (Merck Millipore). The expression of His-tagged CBO1751 
was induced with 1 mM IPTG at 30 °C for 8 h. The expressed protein was purified using metal-chelate affinity 
chromatography with Ni–IDA resin (Merck Millipore) as previously  described51. Eluted proteins were examined 
by SDS-PAGE prior to dialysis (MWCO 8 kDa, Spectrum Labs, New Brunswick, NJ, USA) against 500 ml of 
dialysis buffer (DB: 500 mM NaCl, 50% glycerol, 20 mM Tris–HCl, pH 7.9) overnight at 4 °C. Protein concentra-
tions were determined using the Pierce™ BCA Protein Assay Kit (Thermo Fisher Scientific Oy, Vantaa, Finland) 
with bovine serum albumin (Merck Millipore) as a standard.
Lytic activity analysis. Clostridium strains were cultured to mid-exponential phase  (OD600 0.6–0.7) and 
cells were collected by centrifugation at 5000 × g for 5 min. Pellets were washed gently, resuspended in PBS buffer 
and adjusted to approximately  OD600 of 1. A stock of purified CBO1751 was concentrated by Amicon Ultra-15 
centrifugal filter (Merck Millipore) and adjusted by DB to the concentration of 200 µM for lytic activity analysis. 
Turbidity reduction assay was made by measuring the  OD600 of the cell suspensions immediately after adding 
CBO1751 in a 96-well plate in a volume of 200 µl/well using Multiskan™ Ascent microplate reader (Thermo 
Fisher Scientific). For each reaction, 195 µl of cell suspension was mixed with 5 µl of DB-diluted CBO1751 to 
reach final concentrations of 0.2 to 5 µM, or with 5 µl DB as control and incubated at room temperature. The 
 OD600 of the cell suspensions was measured every 5 min over 60 min. Cell counts were determined after treat-
ment for 60 min using the MPN method as  described52.
To determine the lytic activity, a frozen cell stock was prepared from C. botulinum ATCC3502 grown until 
 OD600 0.6–0.7. Cells were washed gently, resuspended in 20% glycerol and flash frozen in liquid nitrogen. Tur-
bidity reduction assay was conducted as above except that  OD600 was measured every 30 s over 30 min. Data 
analysis was performed as previously  described44,53.  OD600 values were normalized to an initial  OD600 of 1 and 
adjusted by subtracting the corresponding DB control values [adjusted value = normalized value + (1 − normalized 
DB control value)]. The deepest slopes (R2 > 0.995) of lysis curves were selected for linear regression analysis to 
calculate lytic activity. The activity unit was defined as the amount of enzyme resulting in a reduction of 0.001 
OD unit/min in the  OD600 of C. botulinum ATCC3502 frozen cells.
To assess the effect of pH on the CBO1751 lysin activity, frozen C. botulinum ATCC3502 cells were equally 
suspended in universal buffers with pH ranging from 4.5 to 11.5 and adjusted to  OD600 of approximately 1. 
The universal buffer was prepared by mixing 20 mM each of boric acid and phosphoric acid, followed by titra-
tion with sodium  hydroxide54. For each reaction, 195 µl of cell suspension was mixed with 5 µl of DB-diluted 
CBO1751 (final concentration 5 µM) or with 5 µl DB as control. The final pH of each reaction was verified by 
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pH meter. The turbidity reduction assay was carried out at room temperature with the measurement of  OD600 
every 1 min over 60 min. To evaluate the effect of salts on the CBO1751 activity, frozen C. botulinum ATCC3502 
cells were equally distributed in 50 mM Tris–HCl buffer (pH 7.5) with NaCl (final concentration of 12.5, 100, 
200 or 400 mM),  CaCl2 (final concentration of 0, 50, 100 or 200 mM) or  MgSO4 (final concentration of 0, 50, 
100 or 200 mM) and adjusted to  OD600 of approximately 1. Turbidity reduction assay was performed as above 
by adding 5 µl of DB-diluted CBO1751 (final concentration 5 µM) or 5 µl DB to cell suspensions.  OD600 values 
were normalized and adjusted as described above.
All experiments were conducted with three biological replicates. Student’s t-test was used for statistical 
comparisons.
Time-lapse imaging. C. botulinum ATCC3502 spores were prepared as  described55 and fixed into a micro-
fluidic plate using CellASIC ONIX2 microfluidic system (Merck Millipore) according to the manufacturer’s 
instructions in an anaerobic workstation. TPGY medium was perfused into the microfluidic chamber with the 
pressure of 13.8 kPa for 6 h to enable sufficient spore germination. After 20 µM of CBO1751 or control DB was 
perfused into the microfluidic plate to replace TPGY medium, phase-contrast images of newly germinated cells 
were taken every 20 s over 60 min using a Leica DMi8 inverted microscope with a 100-fold oil‐immersion lens 
(Leica Microsystems, Wetzlar, Germany). The images were processed using Metamorph (Universal Imaging, 
Bedford Hills, NY, USA).
Data availability
All data are available from the corresponding authors upon reasonable request.
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